Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.
Actively Recruiting
Healthy Volunteer
Researchers are studying the effectiveness, safety, and tolerability of a vaccine against Clostridioides difficile C. difficile infection in adults aged 65 years and older. The study aims to reduce the number of C. difficile infections, a serious cause of diarrhea, by comparing the vaccine to a placebo. This is a phase 3, randomized, double-blinded trial sponsored by Pfizer. Participants will receive either the C. difficile vaccine or a saline placebo, both given as shots into the upper arm muscle. The study duration varies based on the occurrence of diarrhea events related to C. difficile infection, lasting up to about three and a half years. The study may end earlier if sufficient data is collected or if the vaccine is found ineffective. Vaccination involves two doses, and participants will be closely monitored during and after vaccination. During the study, participants will have three planned clinic visits and three phone visits, followed by annual clinic visits until the study ends. If participants have three or more loose stools in 24 hours, they must save the next stool and contact the study site for infection assessment, which can occur in person or remotely. Researchers will track local and systemic reactions, adverse events, and the incidence of C. difficile infections as primary outcomes over the study period.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new pneumococcal vaccine called PG4 compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC in children and adolescents. The study aims to see how well the new vaccine helps the body fight germs that cause pneumonia, meningitis, and ear infections. It includes children aged 15 months to less than 18 years, some of whom may have previously received pneumococcal vaccines. Participants will be divided into three age groups 15 months to under 2 years, 2 to under 5 years, and 5 to under 18 years. Within each group, participants will be randomly assigned in a 21 ratio to receive a single injection of either the new vaccine PG4 or the existing 20vPnC vaccine, given in the arm or thigh. The study is conducted across multiple countries including the United States and Puerto Rico. Each participant will be involved for about 6 months, attending two clinic visitsone for vaccination and one for follow-upand one telephone follow-up. Blood samples will be collected at visits to measure immune response, and participants will be monitored for local and systemic reactions, adverse events, and serious adverse events throughout the study period. The study evaluates immune system protein levels and antibody activity one month after vaccination to compare the vaccines effects.